You have read all your free articles, to continue reading subscribe to read the rest of this content.
Braeburn Pharmaceuticals and Camurus announces positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 in patients with moderate-to-severe opioid use disorder. "The positive results from this study, coupled with the earlier reported positive results Already a subscriber Login You have read all your…
The first participants have been enrolled into a Phase 1/2 clinical trial of NVAX-CoV2373 which is being conducted at sites in Melbourne and Brisbane, Australia. Preliminary immunogenicity and safety results from the Phase 1 portion of the trial are expected in July 2020. An investment of up to Already a…
The Swedish drug discovery company has announced that the FDA has granted clearance to proceed with VLX600 into the clinical phase I/II. VLX600 is one of the company's drug projects, recently published in the journal Nature Communications. The drug candidate kills sleeping cell populations iAlready a subscriber Login You have read all your free articles,…
Results from the OSTRO Phase III trial showed AstraZeneca’s Fasenra (benralizumab) compared with placebo demonstrated a statistically significant improvement in the size of nasal polyps and in nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Fasenra demonstratAlready a subscriber Login You have read all your free articles, to…
